|Bid||8.75 x 3100|
|Ask||8.77 x 3200|
|Day's range||8.53 - 8.97|
|52-week range||8.06 - 33.79|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.63|
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).
In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss why Inovio Pharmaceuticals' (NASDAQ: INO) technology may result in a longer timeline to commercialization. Corinne Cardina: I have a question for you about the Inovio device. Do you think that this delivery device puts Inovio at a disadvantage compared to vaccines that do not require a device?